ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
07/29/201416:48:45Pfizer Still Looking to Buy; Results Beat Views -- 2nd Update
07/29/201416:33:16MARKET SNAPSHOT: U.S. Stocks End Choppy Trade Lower
07/29/201410:39:16MARKET SNAPSHOT: U.S. Stocks Rise; Dow Above 17,000
07/29/201409:50:28MARKET SNAPSHOT: U.S. Stocks Open Higher; Dow Above 17,000
07/29/201409:33:23MARKET SNAPSHOT: U.S. Stocks: Futures Rise; Housing Prices Next
07/29/201408:15:52MARKET SNAPSHOT: U.S. Stocks: Futures Rise After Merck, Pfizer...
07/29/201407:09:18MARKET SNAPSHOT: U.S. Stocks: Futures Choppy Before Confidence...
07/29/201406:07:35MARKET SNAPSHOT: U.S. Stocks: Futures Decline Before Confidence...
07/07/201415:20:45Novartis Wins 'Breakthrough' Status for Leukemia Treatment
06/09/201417:14:14Merck to Buy Idenix for $3.85 Billion -- 7th Update
06/09/201416:58:36MARKET SNAPSHOT: U.S. Stocks Close Up; S&P 500, Dow At Record
06/09/201413:13:25Merck to Buy Idenix for $3.85 Billion -- 6th Update
06/09/201411:24:46Merck to Buy Idenix for $3.85 Billion -- 5th Update
06/09/201410:53:33MARKET SNAPSHOT: U.S. Stocks Edge Higher; S&P 500 Hits Record
06/09/201409:44:33Merck to Buy Idenix for $3.85 Billion -- 3rd Update
06/09/201409:44:31U.S. Hot Stocks: Hot Stocks to Watch
06/09/201409:00:14Merck to Buy Idenix for $3.85 Billion -- 2nd Update
06/09/201408:29:04Merck to Buy Idenix for $3.85 Billion -- Update
05/13/201407:40:16Merck to Sell Some Ophthalmology Assets
05/08/201410:10:37Merck Plans Phase 3 Trial for Drug for Bone Marrow Transplant...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad